RVL PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -99.00% |
|
-99.00% | -99.97% |
| Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
| Mar. 21 | North American Morning Briefing : Investors -2- | DJ |
Presentation Operator MessageOperator (Operator)Welcome to the RVL Pharmaceuticals Second Quar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
RVL Pharmaceuticals plc is a specialty pharmaceutical company. The Company is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. It is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The Company is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -99.97% | 111 | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -19.27% | 29.48B | |
| +57.86% | 25.43B | |
| -17.69% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B |
- Stock Market
- Equities
- RVLPQ Stock
- News RVL Pharmaceuticals plc
- Transcript : RVL Pharmaceuticals plc, Q2 2022 Earnings Call, Aug 11, 2022
